SCM
EDIT icon

Soleus Capital Management’s Editas Medicine EDIT Stock Holding History

Soleus Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,500
Closed -$965K – 78
2021
Q3 		$965K Sell
23,500
-72,100
-75% -$3.95M 0.15% 65
2021
Q2 		$5.42M Buy
+95,600
New +$3.53M 0.83% 25

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Soleus Capital Management's EDIT Position: Q4 2021 in Review

Soleus Capital Management sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 23,500 shares — an estimated $965K sold.

Soleus Capital Management first reported a position in EDIT in Q2 2021 and held it in 2 quarters. The position peaked at $5.42M in Q2 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Soleus Capital Management reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Soleus Capital Management sold 23,500 Editas Medicine shares in Q4 2021, an estimated $965K.
  • Soleus Capital Management first reported a position in Editas Medicine in Q2 2021 and held it in 2 quarters.
  • Soleus Capital Management's Editas Medicine position peaked at $5.42M in Q2 2021.
  • 305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.